Valliant John 4
4 · Fusion Pharmaceuticals Inc. · Filed Jan 9, 2023
Insider Transaction Report
Form 4
Valliant John
DirectorChief Executive Officer
Transactions
- Award
Stock Option (Right to Buy)
2023-01-05+500,000→ 500,000 totalExercise: $3.75Exp: 2033-01-04→ Common Stock (500,000 underlying)
Footnotes (1)
- [F1]This option vests in 48 equal monthly installments beginning on February 5, 2023.